Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide Duration in High Tumor Burden mHSPC
NCT05956639Phase 3Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rezvilutamide in prostate cancer (PCa) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Radiographic Progression-Free Survival at 36 months. Started Jun 2023; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05956639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956639.